CCL2 and metabolic syndrome: Our previous investigations of atorvastatin and SPM precursors (14HDHA and 17HDHA) determined reduced inflammatory signaling mediators (MIP-2, MCP-1, and IL-6) in both exposed healthy and MetS [11, 13].